USES OF IL-174 ANTAGONISTS FOR INHIBITING A Th2 IMMUNE RESPONSE

1 . A method of:

a) directing a mammalian immune response towards a Th2 type response, said method comprising administering an IL-174 agonist to immune cells of the mammal;

b) stimulating an mammalian innate immune response, said method comprising administering an IL-174 agonist to immune cells of the mammal;

c) augmenting a mammalian inflammatory response from epithelial or fibroblast cells, said method comprising further administering an IL-174 agonist to said mammal;

d) inducing gut cell growth, said method comprising administering an IL-174 agonist to said cell;

e) promoting mammalian extra medulary hematopoiesis, said method comprising administering an IL-174 agonist to said mammal;

f) directing a mammalian immune response away from a Th2 type response, said method comprising administering an IL-174 antagonist to immune cells of the mammal;

g) preventing mammalian inflammation or granuloma formation, comprising administering an IL-174 antagonist to immune system cells; or

h) augmenting antibody response in serum and fecal material, said method comprising administering an IL-174 agonist to immune cells of the mammal.

2 . The method of claim 1 :

a) directing a mammalian immune response towards a Th2 type response, said method comprising administering an IL-174 agonist to immune cells of the mammal;

b) stimulating an mammalian innate immune response, said method comprising administering an IL-174 agonist to immune cells of the mammal;

c) augmenting a mammalian inflammatory response from epithelial or fibroblast cells, said method comprising further administering an IL-174 agonist to said mammal;

d) inducing gut cell growth, said method comprising administering an IL-174 agonist to said cell; or

e) promoting mammalian extra medulary hematopoiesis, said method comprising administering an IL-174 agonist to said mammal.

3 . The method of claim 2 :

d) inducing gut cell growth, said method comprising administering an IL-174 agonist to said cell;

e) promoting mammalian extra medulary hematopoiesis, said method comprising administering an IL-174 agonist to said mammal.

4 . The method of claim 1 :

f) directing a mammalian immune response away from a Th2 type response, said method comprising administering an IL-174 antagonist to immune cells of the mammal;

g) preventing mammalian inflammation or granuloma formation, comprising administering an IL-174 antagonist to immune system cells; or

h) augmenting antibody responses in serum and fecal material, said method comprising administering an IL-174 agonist to immune cells of the mammal.

5 . The method of claim 2 administering an agonist, wherein said administering:

a) induces cytokine production by a fibroblast, epithelial, or endothelial cell;

b) downregulates an inflammatory response which accompanies an infection;

c) stimulates growth of an epithelial cell; or

d) induces growth of gut epithelial, fibroblast, or goblet cells.

6 . The method of claim 2 administering an agonist, wherein said mammal exhibits, or has experienced conditions to stimulate:

a) an autoimmune condition;

b) an infectious disease immune response;

c) a wound healing response; or

d) a Th1 mediated condition.

7 . The method of claim 6 , wherein:

a) said autoimmune condition is selected from:

i) multiple sclerosis;

ii) systemic lupus erythematosis;

iii) rheumatoid arthritis;

iv) diabetes; or

v) psoriasis;

b) said infectious response is symptomatic of:

i) an Aspergillis infection;

ii) a fungal infection, including Candidaisis, Blastomycosis, or Aspergillosis;

iii) a parasitic infection, including Schistosomiasis, fluke worm, Helminth, or Filariasis; or

iv) a viral infection, including hepatitis; or

c) said Th1 mediated condition is an inflammatory condition, including Crohn's disease, ulcerative colitis, pancreatitis, hepatitis, or eosinophilic gastritis.

8 . The method of claim 7 treating an infectious response, further comprising administering another therapeutic entity to treat said infection.

9 . A method of claim 2 , stimulating an mammalian innate immune response.

10 . The method of claim 4 administering an antagonist, wherein said antagonist is a monoclonal antibody against IL-174.

11 . The method of claim 4 administering an antagonist, wherein:

a) said administering blocks eosinophil attraction, tissue remodeling, or fibrosis; or

b) said mammal exhibits, or has experienced conditions to stimulate:

i) an allergic condition;

ii) an inflammatory condition; or

iii) a Th2 mediated condition.

12 . The method of claim 11 , wherein:

a) said eosinophils are attracted to the lung, liver or intestine

b) said fibrosis is pancreatic duct or peribiliary fibrosis;

c) said antagonist suppresses production of IL-4, IL-5, and/or IL-13;

d) said antagonist decreases eotaxin, CCR4, and/or CCR4 expression in BAL;

e) symptoms of said allergic condition are in the lung;

f) said allergic condition is a systemic anaphylactic response, skin hypersensitivity response, or a food allergy; or

g) said inflammatory or Th2 mediated condition is a dermatitis or asthmatic inflammation.

13 . The method of claim 11 , wherein said mammal exhibits, or has experienced conditions to stimulate:

a) an allergic condition;

b) an inflammatory condition; or

c) a Th2 mediated condition.

14 . A composition comprising:

a) an IL-174 agonist and:

i) an antimicrobial, including an antibiotic, antiviral, or antifungal compound; or

ii) a chemotherapy agent; or

b) an IL-174 antagonist and:

i) an allergy medicament;

ii) an asthma medicament;

iii) a dermatitis medicament;

iv) a fibrosis medicament; or

v) an eosinophilic gastritis medicament.